Georges P, Przedborski S, Brotchi J, Chatel M, Gédouin D, Hildebrand J
Service de Neurochirurgie Hôpital Civil Charleroi, Bruxelles, Belgium.
J Neurooncol. 1988 Nov;6(3):211-9. doi: 10.1007/BF00163703.
Forty adults with recurring brain gliomas were treated with HECNU 130 mg/m2, given i.v. every 5 to 6 weeks (mean 5.4) and corticosteroids. According to the response to treatment, patients were divided in 3 groups: 1. Group 1 included 8 pts (20%) with objective remission, defined as a clear-cut clinical improvement persisting at least 4 weeks after the complete discontinuation of corticosteroids. 2. Group 2 included 14 patients (35%) who improved or remained stable yet stayed corticosteroid-dependent. 3. The 18 patients (45%) of group 3 failed to respond. There was a fair correlation between clinical and radiological response. Thus sequential CT-scans showed a 50 to 100% tumour reduction in all patients of group 1, and in 5 of group 2. CT-scans remained unchanged in 8 patients of group 2 and in one of group 3, and showed tumour progression in 10 patients of group 3. Drug toxicity appeared mild, reversible and was not cumulative. The better tolerance of HECNU could represent a real advantage of this drug over the commonly used nitrosourea derivatives such as BCNU and CCNU.
40名复发性脑胶质瘤成年患者接受了130mg/m²的氯乙基亚硝脲静脉注射治疗，每5至6周（平均5.4周）给药一次，并同时使用皮质类固醇。根据治疗反应，患者被分为3组：1. 第1组包括8名患者（20%），达到客观缓解，定义为在完全停用皮质类固醇后至少持续4周的明显临床改善。2. 第2组包括14名患者（35%），病情改善或保持稳定，但仍依赖皮质类固醇。3. 第3组的18名患者（45%）治疗无效。临床反应与放射学反应之间存在一定相关性。因此，连续CT扫描显示第1组所有患者以及第2组5名患者的肿瘤缩小了50%至100%。第2组的8名患者和第3组的1名患者CT扫描结果未改变，第3组的10名患者显示肿瘤进展。药物毒性表现为轻度、可逆且无累积性。氯乙基亚硝脲更好的耐受性可能是该药物相对于常用亚硝基脲衍生物如卡莫司汀和洛莫司汀的真正优势。
